Sirion, Acucela sign deal for gene therapy development

Sirion Biotech and Acucela have signed a 2-year development agreement to establish optimized adeno-associated virus vectors for clinical applications in ocular gene therapy, according to a Sirion press release.
Through the agreement, which Acucela is using to bolster its entrance into the gene therapy market to find a genetic treatment for retinitis pigmentosa, milestone payments will be made to Sirion and additional royalties will be paid on sales from resulting products, the release said.
Sirion, which has been working with viral vector engineering for 10 years, will work with Acucela (Read more...)

Full Story →